Lisanti Capital Growth’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Lisanti Capital Growth’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,980	Closed	-$1.08M	–	186
2023 Q2	$1.08M	Buy	+4,980	New	+$1.07M	0.15%	132
2023 Q1	–	Sell	-6,635	Closed	-$1.3M	–	161
2022 Q4	$1.3M	Sell	6,635 -11,820	-64%	-$2.53M	0.18%	116
2022 Q3	$4.15M	Buy	+18,455	New	+$3.74M	0.56%	72
2020 Q3	–	Sell	-38,290	Closed	-$4.27M	–	151
2020 Q2	$4.27M	Buy	38,290 +23,280	+155%	+$2.02M	0.87%	54
2020 Q1	$1.08M	Buy	+15,010	New	+$1.28M	0.36%	84

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Lisanti Capital Growth's KRTX Position: Q3 2023 in Review

Lisanti Capital Growth sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 4,980 shares — an estimated $1.08M sold.

Lisanti Capital Growth first reported a position in KRTX in Q1 2020 and held it in 5 quarters. The position peaked at $4.27M in Q2 2020. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Lisanti Capital Growth reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Lisanti Capital Growth sold 4,980 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.08M.
Lisanti Capital Growth first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Lisanti Capital Growth's Karuna Therapeutics, Inc. Common Stock position peaked at $4.27M in Q2 2020.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Lisanti Capital Growth's 13F filing for Q3 2023, filed 3 Nov 2023.